VERTEX PHARMACEUTICALS INC / MA (VRTX) Form 10-Q — Aug 4, 2026
Vertex Pharmaceuticals reported Q2 2026 total revenues of $3.33 billion, up 12% year over year, with net income of $1.10 billion and diluted EPS of $4.31 versus $3.99 in Q2 2025. First-half revenues reached $6.32 billion (+10%), and operating cash flow rose to $2.55 billion from $1.89 billion a year ago. Growth was driven by the CF franchise and diversification: ALYFTREK posted $573.6 million in quarterly revenue (+266% YoY, $1.8B since inception), CASGEVY $76.4 million (+151% YoY), and JOURNAVX $49.6 million (+313% YoY). The FDA also approved CASGEVY for children as young as two with sickle cell disease or TDT, adding roughly 5,500 newly eligible patients.
Key figures
- Eps
- 4.31
- Net Income
- 1099.8
- Debt Amount
- No drawn debt as of June 30, 2026; $4.5B senior unsecured term loan and $500M revolver committed July 2026 (undrawn) to fund the Crinetics acquisition
- Revenue Yoy
- +12% (Q2 2026 vs Q2 2025 total revenues)
- Cash Position
- 6143.5
- Shares Outstanding
- 253460924
- Period
- Q2 2026 = three months ended June 30, 2026
- Figures in
- USD millions unless otherwise noted
- Q2 buyback shares
- 1033652
- Casgevy q2 revenue musd
- 76.4
- H1 2026 diluted eps usd
- 8.33
- Alyftrek q2 revenue musd
- 573.6
- Journavx q2 revenue musd
- 49.6
- Q2 buyback avg price usd
- 440.17
- Casgevy q2 yoy growth pct
- 151
- Alyftrek q2 yoy growth pct
- 266
- Journavx q2 yoy growth pct
- 313
- Crinetics equity value busd
- 10
- Crinetics price per share usd
- 85
- Effective tax rate q2 2026 pct
- 21
- Legacy cf products q2 revenue musd
- 137.1
- Buyback authorization remaining busd
- 2.6
Price after filing
Close on the filing date to close N calendar days later (from $481.70). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.